One of the main factors propelling the growth of the market for anthrax treatments is the rise in the number of anthrax victims worldwide. The threat of Bacillus anthracis exposure to civilian populations and military forces is growing, accelerating market growth. Researchers are receiving more funding to develop novel interventions, and this is also accelerating market growth. The rise in public-private partnerships and the expansion of research and development programs for facilitating creative advancements for innovative and efficient treatments are factors that also impact the market. The market for anthrax treatment is likely to develop. However, this is anticipated to be constrained by the high cost of the surgery and treatment as well as strict regulatory requirements for product approval.
The recession is expected to impact the market for anthrax treatments negatively. During a recession, businesses of all sizes see a decline in sales and profits. They might also make it tougher to get paid, harder to acquire financing, and encourage company bankruptcy. Recessions affect every business differently, but some of the difficulties can be anticipated depending on the nature and size of the organization. While clients' late payments can cause problems for a small consulting firm's cash flow, a Fortune 500 business may be able to lower costs by eliminating positions and negotiating better terms with suppliers. Recessions can limit available credit, make it harder to collect debts and lead to company bankruptcy.
Rising Prevalence of Anthrax Infections to Promote Market Growth
One of the key factors propelling the growth of the anthrax treatment market is the rise in the number of anthrax victims worldwide. The threat of exposure to Bacillus anthracis among civilian populations and military forces is rising, and this, combined with an increase in financial support for researchers working on innovative interventions, is accelerating market expansion. Bacterial illnesses are becoming more common everywhere. Anthrax is a bacterial infection brought on by the gram-positive, aerobic, spore-forming bacterium Bacillus anthracis. Depending on how B. anthracis spores enter the body, it typically manifests as a cutaneous, pulmonary, or gastrointestinal infection. The damaged skin area then develops a distinctive black, crusty spot that, after a few weeks, starts to weaken and eventually falls off, leaving a scar. Even though it is uncommon, the course of these occurrences is so typical of the condition that doctors who are familiar with it rarely fail to make the diagnosis.
Rising Cost of Anthrax Treatment to Limit Market Growth
The price of the product is a key consideration in the market. Although there are several diagnostic choices on the market, most people decide to forego getting a diagnosis because of how expensive they are. The test's cost also rose because diagnostic techniques now offer improved sensitivity and specificity. The numerous treatment checkpoints and usage of high-tech modalities for such operations are to blame for the procedure's high cost. The high cost of the treatment is anticipated to reduce market demand because the price of technologically sophisticated instruments drives up the cost of procedures accordingly.
By Anthrax Type
Based on anthrax type, the anthrax treatment market is segmented into cutaneous anthrax, inhalation anthrax, gastrointestinal anthrax and injection anthrax. The inhalation anthrax category dominated the market in 2022. The most deadly type of anthrax is thought to be that which is inhaled. After exposure, infection often appears within a week, although it can take up to two months. Anthrax that is inhaled initially affects the lymph nodes in the chest before spreading to other parts of the body, leading to severe breathing issues and shock. Anthrax inhalation is almost invariably lethal in the absence of therapy.
By Drug Class
Based on drug class, the anthrax treatment market is segmented into antibiotics, immunoglobulins and others. The antibiotics category dominated the market in 2022 because new medicines for the treatment of anthrax are being developed and research funding has increased. The main drivers of the overall market growth include new antibiotic discovery and approval. In order to effectively combat the anthrax bacterium, the number of new and current antibiotics and toxin inhibitors that target both bacterial growth and toxin production have shown increasing promise.
By Distribution Channel
Based on distribution channel, the anthrax treatment market is segmented into hospitals, pharmacies and other distribution channels. The hospital's category dominated the market in 2022 due to the presence of skilled professionals in the hospitals. Additionally, increasing government measures to expand the healthcare infrastructure will help the category thrive.
North America is projected to hold the largest share of the anthrax treatment market over the forecast period due to substantial government financing, encouraging tactics, and the existence of important players in this area. Although anthrax outbreaks in domestic and wild grazing animals like cattle or deer are infrequent, they occasionally happen in the United States. Therefore, it is advised in the US that cattle be vaccinated annually in locations where anthrax has already affected animals. On the other hand, the Asia Pacific anthrax treatment market is anticipated to grow significantly. Market expansion in this region is driven by elements like initiatives by organisations like the CDC promoting the discovery of innovative medicines for the treatment of anthrax. As a result of economic expansion, improved healthcare infrastructure, and a rise in insurance payers, developing nations like China and India are also predicted to drive market demand in the Asia Pacific area in the future.
LIST OF KEY COMPANIES PROFILED:
- Almirall, LLC
- Nighthawk Biosciences, Inc. (Elusys Therapeutics Inc.)
- Paratek Pharmaceuticals, Inc.
- Pfizer Inc.
- Bayer AG
- GSK plc
- Teva Pharmaceutical Industries Ltd.
- In June 2022, it was announced by Emergent BioSolutions Inc. that the U.S. Food and Drug Administration (FDA) had accepted for review the Biologics License Application (BLA) for AV7909, a new anthrax vaccine candidate being tested for post-exposure disease prophylaxis following suspected or confirmed exposure to Bacillus anthracis in people aged 18 to 65 with suggested antibacterial drugs.
|Market Size in 2022
|USD 315.5 Million
|Market Forecast in 2030
|USD 523.4 Million
|Compound Annual Growth Rate
|Revenue (USD Million) and Volume (Kilo Tons)
|By Anthrax Type, By Drug Class, By Distribution Channel and By Geography
|By Anthrax Type
|By Drug Class
|By Distribution Channel